Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 42 articles:
HTML format



Single Articles


    August 2022
  1. ZHANG P, Ono A, Fujii Y, Hayes CN, et al
    The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma.
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34247.
    PubMed     Abstract available


    July 2022
  2. HANG D, Yang X, Lu J, Shen C, et al
    Untargeted plasma metabolomics for risk prediction of hepatocellular carcinoma: A prospective study in two Chinese cohorts.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34229.
    PubMed     Abstract available


  3. COMMANDER SJ, Cerullo M, Arjunji N, Leraas HJ, et al
    Improved Survival and Higher Rates of Surgical Resection Associated with Hepatocellular Carcinoma in Children as Compared to Young Adults.
    Int J Cancer. 2022 Jul 16. doi: 10.1002/ijc.34215.
    PubMed     Abstract available


  4. WEN Q, Chan KH, Shi K, Lv J, et al
    Tobacco smoking and solid fuels for cooking and risk of liver cancer: A prospective cohort study of 0.5 million Chinese adults.
    Int J Cancer. 2022;151:181-190.
    PubMed     Abstract available


  5. FU P, Gong B, Li H, Luo Q, et al
    Combined identification of three lncRNAs in serum as effective diagnostic and prognostic biomarkers for hepatitis B virus-related hepatocellular carcinoma.
    Int J Cancer. 2022 Jul 8. doi: 10.1002/ijc.34201.
    PubMed     Abstract available


    June 2022
  6. NIGER M, Nichetti F, Casadei-Gardini A, Rizzato MD, et al
    Platinum sensitivity in patients with IDH1/2 mutated versus wild-type intrahepatic cholangiocarcinoma: a propensity score-based study.
    Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34182.
    PubMed     Abstract available


  7. ZHENG G, Bouamar H, Cserhati M, Zeballos CR, et al
    Integrin alpha 6 (ITGA6) is upregulated and drives hepatocellular carcinoma progression through integrin alpha6beta4 complex.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34146.
    PubMed     Abstract available


    May 2022
  8. WU H, Zheng X, Pan T, Yang X, et al
    Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma.
    Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34118.
    PubMed     Abstract available


  9. YUN J, Kim YS, Heo MJ, Kim MJ, et al
    ERalpha inhibits mesenchymal and amoeboidal movement of liver cancer cell via Galpha12.
    Int J Cancer. 2022;150:1690-1705.
    PubMed     Abstract available


  10. REINERT T, Petersen LMS, Henriksen TV, Larsen MO, et al
    Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
    Int J Cancer. 2022;150:1537-1548.
    PubMed     Abstract available


    April 2022
  11. CHEN S, Gao Y, Wang Y, Daemen T, et al
    The Combined Signatures of Hypoxia and Cellular Landscape Provides a Prognostic and Therapeutic Biomarker in HBV-Related Hepatocellular Carcinoma.
    Int J Cancer. 2022 Apr 25. doi: 10.1002/ijc.34045.
    PubMed     Abstract available


  12. LIAO W, Du J, Wang Z, Feng Q, et al
    The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma.
    Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34040.
    PubMed     Abstract available


  13. HEMMINKI K, Tichanek F, Forsti A, Hemminki O, et al
    Long-term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast?
    Int J Cancer. 2022 Apr 16. doi: 10.1002/ijc.34031.
    PubMed     Abstract available


    March 2022
  14. VAZ J, Midlov P, Eilard MS, Eriksson B, et al
    Targeting population groups with heavier burden of hepatocellular carcinoma incidence: a nationwide descriptive epidemiological study in Sweden.
    Int J Cancer. 2022 Mar 7. doi: 10.1002/ijc.33993.
    PubMed     Abstract available


    February 2022
  15. SEFRIOUI D, Verdier V, Savoye-Collet C, Beaussire L, et al
    Circulating DNA changes are predictive of disease progression after transarterial chemoembolization.
    Int J Cancer. 2022;150:532-541.
    PubMed     Abstract available


    December 2021
  16. KIM MN, Han K, Yoo J, Ha Y, et al
    Changes in general and central fatness are associated with hepatocellular carcinoma: A Korean nationwide longitudinal study.
    Int J Cancer. 2021 Dec 26. doi: 10.1002/ijc.33920.
    PubMed     Abstract available


  17. TANAKA H, Horioka K, Hasebe T, Sawada K, et al
    Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: a novel therapy exploiting tumor-platelet interactions.
    Int J Cancer. 2021 Dec 22. doi: 10.1002/ijc.33915.
    PubMed     Abstract available


  18. RUTHERFORD MJ, Arnold M, Bardot A, Ferlay J, et al
    Comparison of liver cancer incidence and survival by subtypes across seven high-income countries.
    Int J Cancer. 2021;149:2020-2031.
    PubMed     Abstract available


  19. RIDDER DA, Weinmann A, Schindeldecker M, Urbansky LL, et al
    Comprehensive clinicopathologic study of alpha fetoprotein-expression in a large cohort of patients with hepatocellular carcinoma.
    Int J Cancer. 2021 Dec 11. doi: 10.1002/ijc.33898.
    PubMed     Abstract available


  20. SO R, Chen J, Mehta AJ, Liu S, et al
    Long-term exposure to air pollution and liver cancer incidence in six European cohorts.
    Int J Cancer. 2021;149:1887-1897.
    PubMed     Abstract available


    November 2021
  21. STEPIEN M, Lopez-Nogueroles M, Lahoz A, Kuhn T, et al
    Pre-diagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma.
    Int J Cancer. 2021 Nov 29. doi: 10.1002/ijc.33885.
    PubMed     Abstract available


  22. MOEHLER M, Folprecht G, Heinemann V, Holch JW, et al
    Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).
    Int J Cancer. 2021 Nov 22. doi: 10.1002/ijc.33881.
    PubMed     Abstract available


    September 2021
  23. XU L, Leng C, Chen L, Dong H, et al
    Hypothyroidism is a Predictive Factor of Superior Anti-tumor Efficacy of PD-1 Inhibitors in Hepatocellular Carcinoma.
    Int J Cancer. 2021 Sep 18. doi: 10.1002/ijc.33813.
    PubMed     Abstract available


    August 2021
  24. LIU L, Erickson NT, Ricard I, von Weikersthal LF, et al
    Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized phase III trial FIRE-3 (AIO KRK-0306).
    Int J Cancer. 2021 Aug 25. doi: 10.1002/ijc.33775.
    PubMed     Abstract available


    July 2021
  25. CAO M, Huang W, Chen Y, Li G, et al
    Chronic restraint stress promotes the mobilization and recruitment of myeloid-derived suppressor cells through beta-adrenergic-activated CXCL5-CXCR2-Erk signaling cascades.
    Int J Cancer. 2021;149:460-472.
    PubMed     Abstract available


  26. ZHUO Z, Miao L, Hua W, Chen H, et al
    Genetic variations in nucleotide excision repair (NER) pathway genes and hepatoblastoma susceptibility.
    Int J Cancer. 2021 Jul 1. doi: 10.1002/ijc.33722.
    PubMed     Abstract available


    June 2021
  27. WANG L, Long J, Chen H, Sun S, et al
    Manipulation of focal Wnt activity via synthetic cells in a double-humanized zebrafish model of tumorigenesis.
    Int J Cancer. 2021;148:2815-2824.
    PubMed     Abstract available


    May 2021
  28. LONG L, Liu X, Jin L, Simon T, et al
    Association of bowel movement frequency and laxative use with risk of hepatocellular carcinoma in US women and men.
    Int J Cancer. 2021 May 24. doi: 10.1002/ijc.33699.
    PubMed     Abstract available


    April 2021
  29. MAYEN AL, Aglago EK, Knaze V, Cordova R, et al
    Dietary intake of advanced glycation endproducts and risk of hepatobiliary cancers: a multinational cohort study.
    Int J Cancer. 2021 Apr 25. doi: 10.1002/ijc.33612.
    PubMed     Abstract available


  30. LU L, Xing K, Wei W, Ling Y, et al
    Immune-related adverse events predict responses to PD-1 blockade immunotherapy in hepatocellular carcinoma.
    Int J Cancer. 2021 Apr 22. doi: 10.1002/ijc.33609.
    PubMed     Abstract available


  31. ZHU HB, Xu D, Ye M, Sun L, et al
    Deep learning-assisted magnetic resonance imaging prediction of tumor response to chemotherapy in patients with colorectal liver metastases.
    Int J Cancer. 2021;148:1717-1730.
    PubMed     Abstract available


    March 2021
  32. WASHINGTON MK, Goldberg RM, Chang GJ, Limburg P, et al
    Diagnosis of digestive system tumours.
    Int J Cancer. 2021;148:1040-1050.
    PubMed     Abstract available


    November 2020
  33. HEO MJ, Kang SH, Kim YS, Lee JM, et al
    UBC12-mediated SREBP-1 neddylation worsens metastatic tumor prognosis.
    Int J Cancer. 2020;147:2550-2563.
    PubMed     Abstract available


  34. CHENG C, Zhao Y, Schaafsma E, Weng YL, et al
    An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
    Int J Cancer. 2020;147:2621-2633.
    PubMed     Abstract available


    October 2020
  35. THURMAIER J, Heinemann V, Engel J, Schubert-Fritschle G, et al
    Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival.
    Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33364.
    PubMed     Abstract available


  36. SCHLICKER A, Ellappalayam A, Beumer IJ, Snel MHJ, et al
    Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.
    Int J Cancer. 2020;147:2303-2315.
    PubMed     Abstract available


    September 2020
  37. FRENCH B, Sadakane A, Cologne J, Mabuchi K, et al
    Misclassification of primary liver cancer in the Life Span Study of atomic bomb survivors.
    Int J Cancer. 2020;147:1294-1299.
    PubMed     Abstract available


  38. GIANNINI V, Rosati S, Defeudis A, Balestra G, et al
    Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy.
    Int J Cancer. 2020 Sep 1. doi: 10.1002/ijc.33271.
    PubMed     Abstract available


    August 2020
  39. ZHONG GC, Wang K, Peng Y, Shivappa N, et al
    Dietary inflammatory index and incidence of and death from primary liver cancer: A prospective study of 103,902 American adults.
    Int J Cancer. 2020;147:1050-1058.
    PubMed     Abstract available


    July 2020
  40. LINDNER AU, Carberry S, Monsefi N, Barat A, et al
    Systems analysis of protein signatures predicting Cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenografts models of metastatic colorectal cancer.
    Int J Cancer. 2020 Jul 23. doi: 10.1002/ijc.33226.
    PubMed     Abstract available


    February 2020
  41. ZHONG GC, Peng Y, Wang K, Wan L, et al
    Magnesium intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2020 Feb 27. doi: 10.1002/ijc.32939.
    PubMed     Abstract available


    December 2019
  42. WOLSTENHOLME J, Fusco F, Gray AM, Moschandreas J, et al
    Quality of life in the FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised trials of selective internal radiotherapy for metastatic colorectal cancer.
    Int J Cancer. 2019 Dec 16. doi: 10.1002/ijc.32828.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: